Clinical Trials · NCT05918302
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Enrollment
- 170
- Start date
- Oct 2023
- Locations
- 27 sites, 4 countries
- Primary endpoint
- Progression-free survival (PFS)